Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

Inclusion Criteria:

• Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012
• Patients who have been informed and who have given their written consent for the access to their medical file

Exclusion Criteria:

• Patients already included in a Plerixafor ongoing clinical trial.